1. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
- Author
-
Kim SG, Kim KJ, Yoon KH, Chun SW, Park KS, Choi KM, Lim S, Mok JO, Lee HW, Seo JA, Cha BS, Kim MK, Shon HS, Choi DS, and Kim DM
- Subjects
- Blood Glucose, Double-Blind Method, Drug Therapy, Combination, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents adverse effects, Pyrimidines, Sitagliptin Phosphate adverse effects, Thiazolidinediones, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Metabolic Syndrome, Metformin adverse effects
- Abstract
We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%; P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF